Gerresheimer Faces Critical Audit Deadline Amid Deepening Crisis

The German pharmaceutical packaging specialist Gerresheimer finds itself navigating its most severe corporate turmoil in recent memory. A combination of accounting irregularities, dual regulatory probes, and a leadership vacuum has placed immense pressure on the company. The pivotal date now looming is March 31, 2026, by which management must present a certified annual financial statement to begin restoring market confidence.

Leadership Void and Operational Strain

The company’s top ranks have been destabilized. CEO Dietmar Siemssen departed at the end of October, with CFO Bernd Metzner following shortly after. Since then, Uwe Röhrhoff has been leading on an interim basis, with Wolf Lehmann assuming the CFO role. This executive uncertainty compounds significant operational headwinds.

For the 2025 fiscal year, Gerresheimer anticipates a revenue decline at the weaker end of its previously guided range of minus 4 to minus 2 percent. Its adjusted EBITDA margin forecast has been lowered to 16.5 to 17.5 percent, down from 18.5 to 19.0 percent. Adjusted earnings per share could even turn negative. Further strain comes from impairment charges totaling 220 to 240 million euros, primarily related to its Sensile Medical subsidiary and a US facility in Chicago.

Twin BaFin Investigations Unfold

Regulatory scrutiny intensified in late February. Germany’s financial watchdog, BaFin, is now conducting two parallel examinations. One focuses on the consolidated financial statements for 2024, while a second, newly launched probe targets the 2025 half-year report. Central to the investigations are “bill-and-hold” agreements, a practice where revenue is recognized before physical delivery of goods.

Specific potential errors have been identified in the 2023/24 accounts, including possibly misstated lease liabilities of 65.5 million euros and capitalized development costs of 29.4 million euros. The firm has acknowledged that certain employees may have violated internal policies and accounting rules. A second auditing firm has been engaged to scrutinize revenue recognition and accounting practices for both 2024 and 2025.

Strategic Moves to Shore Up the Balance Sheet

In response to the financial strain, management plans to divest its US subsidiary, Centor—a profitable manufacturer of packaging systems for prescription drugs. Morgan Stanley is slated to oversee the sale process, targeted for 2026. This move presents a dilemma, as Centor’s above-average profitability means its sale would further pressure the group’s already declining margin structure.

Should investors sell immediately? Or is it worth buying Gerresheimer?

Conversely, the moulded glass business will be retained. The company plans to shutter its Chicago Heights site by the end of 2026. These actions aim to alleviate balance sheet pressures stemming from the substantial impairments.

Market Reaction and a Glimmer of Confidence

The equity market has priced in the crisis aggressively. From a 52-week high of 82 euros—fueled by takeover speculation that dissolved in the summer of 2025—the share price plummeted to a 10-year low by the end of February. It currently trades approximately 43 percent below its 200-day moving average, with its Relative Strength Index (RSI) at 17.7, deep in oversold territory.

Despite the bleak outlook, the CastleKnight Master Fund LP reported a 4.08 percent voting rights stake in early March, dated February 11, 2026. This suggests some investors perceive a potential turnaround opportunity. Meanwhile, the Deutsche Schutzvereinigung für Wertpapierbesitz (DSW) is examining potential claims for damages on behalf of shareholders.

The Make-or-Break Timeline

Looking ahead to 2026, Gerresheimer has provided guidance forecasting revenue of 2.3 to 2.4 billion euros and an adjusted EBITDA margin of 18 to 19 percent. The credibility of these targets hinges almost entirely on the successful delivery of a certified annual report by the March 31 deadline.

A timely submission with clear, understandable corrections could alleviate a portion of the prevailing uncertainty. Another delay, however, would likely keep the stock depressed near its multi-year lows. Investors will also be closely watching the Q1 trading update on April 16 and the Annual General Meeting scheduled for June 3, 2026.